Evaluating Ginkgo Bioworks Holdings: Insights From 4 Financial Analysts
Portfolio Pulse from Benzinga Insights
Ginkgo Bioworks Holdings (NYSE:DNA) has received mixed reviews from financial analysts, with 2 bearish and 2 indifferent ratings in the past quarter. The average 12-month price target is $1.8, up from the previous $1.25, with a high estimate of $2.50 and a low of $1.10. Goldman Sachs analyst Matthew Sykes lowered the price target to $1.10 from $1.25, maintaining a 'Sell' rating, while Raymond James analyst Rahul Sarugaser announced a 'Market Perform' rating with a $2.50 target. Ginkgo Bioworks faces challenges with a -16.52% revenue decline, a net margin of -546.44%, and an ROE of -21.98%, but maintains a low debt-to-equity ratio of 0.32.
January 23, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ginkgo Bioworks Holdings has a mixed outlook from analysts, with a recent price target decrease by Goldman Sachs and a new market perform rating from Raymond James. The company struggles with revenue and profitability but has a low debt ratio.
The bearish sentiment from analysts, especially the lowered price target from Goldman Sachs, suggests a negative short-term impact on DNA's stock price. The company's financial challenges, such as declining revenue and negative profitability metrics, reinforce the potential for a downward price movement. However, the low debt ratio may provide some support to the stock price.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100